The prevalence of clinically significant portal hypertension (CSPH) is high in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT).
There was no evidence of whether primary prophylaxis is beneficial in reducing hepatic decompensation in these patients.
